| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
108,674,000 |
| Market
Cap: |
57.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2298 - $2.31 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 707 |
| Guru Rank Value : 1.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
816,825 |
816,825 |
| Total Buy Value |
$0 |
$0 |
$194,885 |
$194,885 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
4 |
4 |
| Total Shares Sold |
211,204 |
267,396 |
419,842 |
591,605 |
| Total Sell Value |
$130,313 |
$170,773 |
$340,560 |
$980,941 |
| Total People Sold |
5 |
5 |
6 |
9 |
| Total Sell Transactions |
5 |
10 |
23 |
41 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2018-07-26 |
4 |
AS |
$39.02 |
$152,221 |
I/I |
(3,900) |
93,778 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2018-07-10 |
4 |
AS |
$39.93 |
$1,137,733 |
I/I |
(28,400) |
97,678 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2018-07-09 |
4 |
AS |
$39.88 |
$1,198,006 |
I/I |
(30,000) |
126,078 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2018-06-27 |
4 |
AS |
$37.57 |
$76,055 |
I/I |
(2,000) |
156,078 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2018-06-26 |
4 |
AS |
$40.01 |
$177,370 |
I/I |
(4,400) |
158,078 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2018-06-18 |
4 |
AS |
$44.68 |
$111,944 |
D/D |
(2,500) |
110,192 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
21,854 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
112,692 |
|
- |
|
| Marcus Joel S |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
8,500 |
|
- |
|
| Dobmeier Eric |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
14,000 |
|
- |
|
| Heiden William K |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
8,500 |
|
- |
|
| Seidenberg Beth C |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
15,189 |
|
- |
|
| Koppikar Utpal |
Chief Financial Officer |
• – – |
2018-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
45,000 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2018-06-06 |
4 |
AS |
$46.53 |
$208,532 |
I/I |
(4,400) |
162,478 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2018-06-05 |
4 |
AS |
$49.51 |
$218,756 |
I/I |
(4,400) |
166,878 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2018-05-22 |
4 |
AS |
$50.88 |
$223,872 |
I/I |
(4,400) |
171,278 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2018-05-21 |
4 |
AS |
$51.67 |
$231,441 |
I/I |
(4,400) |
175,678 |
|
- |
|
| Clark Mitchall G. |
EVP & Chief R & QA Officer |
• – – |
2018-05-18 |
4 |
AS |
$50.03 |
$1,293,776 |
D/D |
(25,860) |
107,972 |
|
- |
|
| Clark Mitchall G. |
EVP & Chief R & QA Officer |
• – – |
2018-05-16 |
4 |
AS |
$46.04 |
$214,026 |
D/D |
(4,647) |
133,832 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2018-05-16 |
4 |
AS |
$46.06 |
$12,574 |
D/D |
(273) |
111,192 |
|
- |
|
| Haqq Christopher |
EVP, R&D & Chief Scientific Of |
• – – |
2018-05-15 |
4 |
AS |
$44.44 |
$1,167,480 |
D/D |
(25,775) |
332,130 |
|
- |
|
| Haqq Christopher |
EVP, R&D & Chief Scientific Of |
• – – |
2018-05-15 |
4 |
OE |
$11.00 |
$275,000 |
D/D |
25,000 |
357,905 |
|
- |
|
| Clark Mitchall G. |
EVP & Chief R & QA Officer |
• – – |
2018-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,808 |
138,479 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2018-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
545 |
111,465 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2018-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
534 |
20,354 |
|
- |
|
736 Records found
|
|
Page 13 of 30 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (7.08%) 
